Evidence map›Paper›PMID 40065917›Full record

ArticleAlzheimer's & dementia (New York, N. Y.)

Broad repetitive transcranial magnetic stimulation (rTMS) of the precuneus in Alzheimer's disease: A rationale and study design.

Michael K Leuchter, Hanadi A Oughli, Kelly A Durbin, Nicholas J Jackson, David Elashoff, Timothy S Chang, Juliana Corlier, Doan Ngo, Cole Matthews, Darice Wong and 5 more

Registry-linked trialAbstract read
In one paragraph

Article in Alzheimer's & dementia (New York, N. Y.). The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06597942 (Protocol for Maintaining and Improving Mental Status in Alzheimer's Disease), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06597942 phase1 / phase2recruitingnot on this map

Protocol for Maintaining and Improving Mental Status in Alzheimer's Disease (PROMIS-AD): a Pilot Study of Repetitive Transcranial Magnetic Stimulation of the Precuneus for Alzheimer&Amp;Amp;#39;s Disease

TypeinterventionalSponsorUniversity of California, Los AngelesRan2024 to 2026Enrolled54ConditionsAlzheimer&Amp, Amp, #39, s DiseaseArmsTMS, Transcranial Magnetic Stimulation Sham
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Michael K LeuchterTMS Clinical and Research Program, Neuromodulation Division Semel Institute for Neuroscience and Human Behavior at UCLA Los Angeles California USA.ORCID https://orcid.org/0000-0002-9060-6721
Hanadi A OughliTMS Clinical and Research Program, Neuromodulation Division Semel Institute for Neuroscience and Human Behavior at UCLA Los Angeles California USA.
Kelly A DurbinTMS Clinical and Research Program, Neuromodulation Division Semel Institute for Neuroscience and Human Behavior at UCLA Los Angeles California USA.
Nicholas J JacksonDepartment of Medicine Statistics Core David Geffen School of Medicine at UCLA Los Angeles California USA.
David ElashoffDepartment of Medicine Statistics Core David Geffen School of Medicine at UCLA Los Angeles California USA.
Timothy S ChangMary S. Easton Center for Alzheimer's Disease Research, Department of Neurology David Geffen School of Medicine at UCLA Los Angeles California USA.
Juliana CorlierTMS Clinical and Research Program, Neuromodulation Division Semel Institute for Neuroscience and Human Behavior at UCLA Los Angeles California USA.
Doan NgoTMS Clinical and Research Program, Neuromodulation Division Semel Institute for Neuroscience and Human Behavior at UCLA Los Angeles California USA.
Cole MatthewsTMS Clinical and Research Program, Neuromodulation Division Semel Institute for Neuroscience and Human Behavior at UCLA Los Angeles California USA.
Darice WongUCLA Clinical Neurogenomics Research Center, David Geffen School of Medicine University of California Los Angeles California USA.
Brent L FogelUCLA Clinical Neurogenomics Research Center, David Geffen School of Medicine University of California Los Angeles California USA.
Gal BitanDepartment of Neurology David Geffen School of Medicine at UCLA Los Angeles California USA.
Andrew F LeuchterTMS Clinical and Research Program, Neuromodulation Division Semel Institute for Neuroscience and Human Behavior at UCLA Los Angeles California USA.
Keith VosselMary S. Easton Center for Alzheimer's Disease Research, Department of Neurology David Geffen School of Medicine at UCLA Los Angeles California USA.
Nanthia SuthanaTMS Clinical and Research Program, Neuromodulation Division Semel Institute for Neuroscience and Human Behavior at UCLA Los Angeles California USA.

Funding

Multi-target repetitive Transcranial Magnetic Stimulation (rTMS) treatment for Major Depressive Disorder (MDD) and comorbid painK01MH123887 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Juliana Corlier · 2022 to 2026
$732k
NIMH NIH HHS K01 MH123887
6 · The paper itself

Abstract

introductionBrain network dysfunction, particularly within the default mode network (DMN), is an increasingly apparent contributor to the clinical progression of Alzheimer's disease (AD). Repetitive transcranial magnetic stimulation (rTMS) can target key DMN hubs, maintain signaling function, and delay or improve clinical outcomes in AD. Here, we present the rationale and design of a study using off-the-shelf equipment and the latest clinical evidence to expand on prior rTMS work and reduce participant burden in the process.

methodsWe will conduct a two-stage trial of large-coil rTMS targeting the precuneus (a key hub in the DMN affected by AD) in 54 participants with mild to moderate Alzheimer's Clinical Syndrome focused primarily on determining tolerability and feasibility and secondarily focused on determining short-term efficacy for memory. The first stage will involve 5 to 10 participants receiving open-label active treatment to refine the protocol. The following second stage will consist of a 1:1 randomized, double-blind, sham-controlled clinical trial to study feasibility and tolerability while exploring target engagement and short-term efficacy for memory. Participants will undergo 16 total rTMS brain stimulation sessions over the course of 5 weeks. A full course of open-label active treatment will be offered as an extension to the sham group after unblinding. Outcomes will focus on completion rates and adverse events to demonstrate feasibility and tolerability. Further exploratory outcomes will include neuropsychological assessments, electroencephalography, neuroimaging, and blood biomarkers to demonstrate the feasibility of collection and explore preliminary changes in these measures.

resultsWe anticipate this treatment is feasible and tolerable and may show evidence of target engagement and clinical improvement. DISCUSSION: Should we achieve expected positive outcomes in feasibility and tolerability, this will justify future work focusing on clear demonstrations of clinical efficacy and biomarker engagement, as well as enhancement of generalizability and scalability. Highlights: Induction-to-maintenance repetitive transcranial magnetic stimulation (rTMS) of the precuneus is a promising treatment for Alzheimer's disease (AD), though recent methods require intensive personalization.We propose here a trial design of precuneus rTMS in mild-to-early-moderate AD dementia using exclusively off-the-shelf equipment and protocol modifications to reduce participant burden.Our two novel modifications from prior work are (1) using a larger rTMS coil, and (2) consolidating the induction phase of treatment.This trial focuses primarily on tolerability and feasibility while exploring clinical measures of efficacy and biomarkers of target engagement.Our trial is registered at ClinicalTrials.gov NCT06597942.

Indexed as

Alzheimer's diseasedeep repetitive transcranial magnetic stimulationdefault mode networkprecuneusrepetitive transcranial magnetic stimulation

Identifiers

PMID40065917
PMCPMC11891574

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.